The Next Frontier of Drug Discovery

Ribometrix is leading a new drug-discovery paradigm: using small molecules to target RNA biology and prevent the production of proteins that drive disease.

Ribometrix Lab

The Ribometrix Difference

Discover the Next Big Biological Breakthrough

Unlike conventional therapeutic pipelines which largely target proteins, we are developing small molecule drugs that prevent disease-causing proteins from ever being made.

Create the Future With Us

We’ve teamed up with strategic partners who are helping us advance the new frontier of direct RNA targeting.

The Potential to Change Lives

When we disrupt the right RBP-RNA interaction, we directly affect function and can help patients fight life-threatening diseases.

Cell Proliferation Disorders

Targeting RNA biology provides us with a unique approach to tackle difficult-to-drug oncogenes.

Central Nervous System

Targeting RNA biology unlocks opportunities to manipulate key nodes of regulation across an array of serious, functionally complex CNS disorders.

Autoimmune Disorders

Targeting RNA biology with small molecules allows us to develop oral drugs for autoimmune diseases and the opportunity to drug intracellular targets inaccessible to biologics.

About Ribometrix

Headquartered in Research Triangle Park, we’ve built the leading industry platform for discovering and developing therapies that modulate RNA biology.

Ribometrix scientist
Ribometrix team meeting
Ribometrix lab

Leaders in Small Molecule Drugs

Our team of RNA experts and drug discovery specialists brings decades of experience to the Ribometrix mission.

Ribometrix team members
Careers

Enjoy a Life-Changing Career at Ribometrix

Cutting-edge technology. Game-changing medical breakthroughs. Working alongside the most passionate scientific leaders in RNA biology. Ribometrix is a unique opportunity to trailblaze the next frontier in drug discovery.

“Targeting RNA is a potentially powerful new approach for developing small molecule therapeutics, and Ribometrix has developed an innovative technology for the accelerated discovery of selective candidates in this new space.”
Mark Bunnage, Senior Vice President and Site Head, Boston Research

Vertex Pharmaceuticals Incorporated
“Through extraordinary commitment and scientific rigor, Ribometrix is now on the verge of opening a new horizon in drug discovery — RNA modulation by small molecules.”
Mike Clayman, Chairman of the Board
Ribometrix

Connect With Us

For more information, or interest in partnerships, please fill out the form.